Source: T01
Original URL: https://www.obipharma.com/what-we-do/pipeline-overview/
Title: OBI Pharma — Pipeline
Original source_date: unknown
Original data_date: unknown
Checked_at: 2026-10-07T10:46:10.944263+00:00
Timezone: Etc/UTC
Retrieval mode: live_public_web_tool
Read level: targeted_public_HTML_passages
Access result: specified public URL returned readable content; no access barrier encountered
Material type: minimum excerpt/numeric-support record authored from the observed public source, not the full original webpage/PDF.
The SHA256 of this .txt identifies this excerpt record only. Original webpage/PDF bytes were not saved.
Locators:
- OBI-992: web lines 116–138; mechanism at line 133; study status at line 137
- OBI-902: web lines 145–169; mechanism at lines 163–164; study status at line 168
Minimum verbatim excerpts:
- web line 163: OBI-902 is OBI’s next-generation TROP2-targeted ADC.
- web line 163: proprietary glycan-based site-specific platform GlycOBI
- web line 133: via a cysteine conjugated, hydrophilic and enzyme-cleavable linker.
Numeric / structured original fields (not market estimates):
Supported scope (author paraphrase, not original quotation):
公司管線頁區分OBI-902的TROP2／GlycOBI醣位點設計與OBI-992的半胱胺酸偶聯，並述人體研究；產品差異仍須人體資料支持。
Precise evidence gap / boundary:
原頁未標發布或更新日；這是本輪公開頁讀取，不是具日期的歷史快照。公司工程優勢不當成人體優效。
Web references: turn113view0